Publicacións en colaboración con investigadores/as de Aarhus University Hospital (23)

2024

  1. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

    The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389

  2. Quantification of temporomandibular joint space in patients with juvenile idiopathic arthritis assessed by cone beam computerized tomography

    Orthodontics and Craniofacial Research, Vol. 27, Núm. 2, pp. 203-210

2023

  1. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 1, pp. 48-56

  2. Association of vocational interventions and work-related factors with disease and work outcomes in people with RMDs: A systematic review

    Seminars in Arthritis and Rheumatism, Vol. 58

  3. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

    Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019

2022

  1. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366

  2. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): Systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

    RMD Open, Vol. 8, Núm. 2

  3. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

    RMD open, Vol. 8, Núm. 1

  4. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

    Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807

  5. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

    Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218

  6. Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

    RMD open, Vol. 8, Núm. 1

  7. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751

2021

  1. 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 707-713

  2. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 10, pp. 1278-1285

2020

  1. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

    RMD open, Vol. 6, Núm. 3

  2. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2455-2461

  3. Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: Systematic reviews informing the 2020 EULAR points to consider

    RMD Open, Vol. 6, Núm. 3

2017

  1. Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration

    Journal of Rheumatology, Vol. 44, Núm. 2, pp. 162-169

2016

  1. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration

    Arthritis Research and Therapy, Vol. 18, Núm. 1

  2. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration [Arthritis Res Ther. 18: (2016); 50], doi: 10.1186/s13075-016-0951-z

    Arthritis Research and Therapy